(Part 2) Normal Secondary Hemostasis

Describe the role of antithrombin, Tissue Factor Pathway Inhibitor, Protein C, and Protein S in inhibiting clot formation

Antithrombin

• Snergistically with herparin

• targets factor 10 and thrombin

Tissue Factor Pathway Inhibitor

• Binds to tissue factor preventing it to bind to Factor 7

• targets factor 10

Protein C

• works with Protein S

• Targets Factor 5 and 8

  • cofactors accelerate process in coagulation casacde

• Activated by thrombomodulin

Protein S

• Activated protein C binds to Protein S

  • Inactivates Va and factor 8a

  • Control mechanism that slows thrombin generation

• Binds to complement component C4b (acute phase reactant)

  • less available in inflammatory events

Outline the in vitro coagulation cascades (i.e. intrinsic, extrinsic, and common pathways) in the correct order

The Extrinsic Pathway

This pathway is initiated by the release of factors not normally found in the blood.

• Initiation: Triggered by vessel injury, which releases Tissue Factor (TF or Factor III) from the endothelium into the circulation.

• Activation: Tissue Factor binds to Factor VII.

• Complex Formation: This creates the Extrinsic Xase complex (consisting of Tissue Factor, activated Factor VIIa, and Calcium), which directly activates Factor X to begin the common pathway.

2. The Intrinsic (Contact) Pathway

This pathway involves factors that already circulate in the blood in an inactive form and requires exposure to a "foreign" or negative surface for initiation.

• Initiation: The contact phase begins with the activation of Factor XII to XIIa.

• Sequential Activation:

  • XIIa activates Factor XI to XIa.

  • XIa, in the presence of calcium (Ca++), activates Factor IX to IXa.

• Complex Formation: Factor IXa combines with activated Factor VIIIa, phospholipids (PL), and calcium to form the Intrinsic Xase complex, which then activates Factor X.

3. The Common Pathway

Both the intrinsic and extrinsic pathways converge at this stage to produce the final fibrin clot.

• Activation of Factor X: The pathway begins when Factor X is converted to Xa.

• Prothrombinase Complex: Factor Xa combines with Factor Va, phospholipids, and calcium to form the Prothrombinase complex.

• Thrombin Generation: This complex converts Prothrombin (Factor II) into Thrombin (IIa).

• Fibrin Production: Thrombin (IIa) performs the following critical actions:

  • It cleaves Fibrinogen (Factor I) into Fibrin monomers.

  • It activates Factor XIII into XIIIa.

  • It provides feedback by activating Factors VIII and V.

• Stable Clot Formation: Finally, Factor XIIIa crosslinks the fibrin monomers to form a stable fibrin polymer, resulting in a visible blood clot

State what factors belong to the intrinsic, extrinsic, and common pathways

Intrinsic Pathway (Contact System)

This pathway includes factors that circulate in the blood in an inactive form and requires exposure to a foreign surface for initiation.

• Prekallikrein (PK)

• High-molecular-weight kininogen (HK)

• Factor XII

• Factor XI

• Factor IX

• Factor VIII

Extrinsic Pathway

This pathway is initiated by the release of Tissue Factor into the circulation.

• Factor VII

• Factor III (Tissue Factor)

Common Pathway

The intrinsic and extrinsic pathways converge here to produce the final fibrin clot.

• Factor X

• Factor V

• Factor II (Prothrombin)

• Factor I (Fibrinogen)

Compare and contrast the in vivo and in vitro cascades

Key Differences

• Initiation and Primary Pathway:

  • In Vivo: The primary trigger for normal clot formation in the body is vessel injury, which releases Tissue Factor (TF) from the endothelium into the circulation. This makes the extrinsic pathway the dominant initiator of clotting in a living system.

  • In Vitro: Laboratory tests are designed to isolate and measure specific pathways. The Intrinsic Pathway is initiated in the lab by exposing plasma to negative/foreign surfaces (such as Kaolin or glass) to trigger the contact phase, whereas the Extrinsic Pathway is initiated by adding reagents like tissue thromboplastin.

• The Role of the Contact (Intrinsic) Pathway:

  • In Vivo: The contact activation pathway (Factors XII, XI, PK, and HK) does not directly contribute to normal clot formation in the body. Instead, it plays a role in inflammation, blood pressure regulation, and fibrinolysis.

  • In Vitro: This pathway is a critical component of laboratory screening, specifically measured by the Activated Partial Thromboplastin Time (aPTT) test to evaluate the activity of factors like VIII, IX, XI, and XII.

• Integration vs. Isolation:

  • In Vivo: The pathways are highly interconnected. For example, the Factor VIIa/Tissue Factor complex (part of the extrinsic pathway) can directly activate Factor IX (part of the intrinsic pathway) to amplify the cascade.

  • In Vitro: Laboratory testing cannot mimic the cascade as it is found in vivo. Instead, it uses separate tests—the Prothrombin Time (PT) for the extrinsic pathway and the aPTT for the intrinsic pathway—to pinpoint exactly which factors may be deficient.

• Regulatory Mechanisms:

  • In Vivo: The body employs complex control mechanisms to prevent runaway clotting, such as Tissue Factor Pathway Inhibitor (TFPI), Antithrombin, and the Protein C & S system.

  • In Vitro: Lab tests focus on the time it takes to form a clot under specific conditions and are often used to monitor the effectiveness of anticoagulant drugs like Warfarin (monitored via PT/INR) or to detect heparin contamination (via Thrombin Time).

Key Similarities

• The Common Pathway: Both processes converge at the same point, beginning with the activation of Factor X.

• Final Result: Both ultimately lead to the generation of thrombin (IIa), which cleaves fibrinogen into fibrin monomers that are crosslinked by Factor XIIIa to form a stable fibrin polymer.

• Required Components: Both requires the presence of calcium (Ca++) and phospholipids (derived from platelet membranes in vivo or added as reagents in vitro) to form the necessary enzyme complexes

Describe contact activation and list the substances involved

Contact activation is the process that initiates the intrinsic pathway of the coagulation cascade. While it does not directly contribute to normal clot formation in the body (in vivo), it is a critical component of laboratory coagulation testing (in vitro).

Substances Involved

The contact activation phase involves a specific group of factors and surfaces:

• Coagulation Factors:

  • Factor XII (Hageman factor)

  • Factor XI

  • Prekallikrein (PK)

  • High-molecular-weight kininogen (HK)

• Surfaces and Cofactors:

  • Negative/Foreign Surfaces: Required for initiation (e.g., glass or kaolin in a lab setting).

  • Phospholipids: Derived from the platelet membrane.

  • Calcium (Ca++): Necessary for subsequent steps in the pathway, such as the activation of Factor IX by Factor XIa

Associate the in vitro coagulation pathway with the screening test it measures

• Extrinsic Pathway: This pathway is measured by the Prothrombin Time (PT) test. The test is performed by adding tissue thromboplastin (Factor III) and calcium to the patient's plasma to initiate the cascade through Factor VII. Clinically, the PT is often used to monitor the levels of anticoagulant medications like warfarin.

• Intrinsic Pathway: This pathway is measured by the Activated Partial Thromboplastin Time (aPTT) test. To mimic the contact phase in vitro, reagents such as kaolin (a negative surface) and phospholipids are added to the plasma. This test evaluates the activity of factors XII, XI, IX, and VIII.

• Common Pathway: Both the PT and aPTT evaluate the common pathway, as both tests culminate in the formation of a fibrin clot. However, more specific tests exist for the final steps of this pathway:

  • Thrombin Time: Directly measures the conversion of fibrinogen to fibrin by adding thrombin to the plasma; it is highly useful for detecting heparin contamination.

  • Fibrinogen Assay: Determines the actual concentration of fibrinogen (Factor I) by comparing clotting times to a calibration curve.

If a primary screening test like the PT or aPTT is prolonged, Factor Assays are employed to identify the specific factor deficiency by testing the patient's plasma against known factor-deficient plasma

Identify the special precautions that must be taken in the collection and handling of coagulation samples (be sure to know stability)

• Anticoagulant Requirement: Coagulation tests, such as the aPTT and PT, require the use of citrated plasma.

• Avoidance of Contamination: A key precaution in sample handling is preventing heparin contamination, which can interfere with results. The Thrombin Time test is explicitly mentioned as being useful for detecting such contamination.

• Procedural Handling (aPTT): During the testing process for the aPTT, the source indicates that the calcium (Ca++) must be added after an incubation period with the kaolin and phospholipids to properly initiate the cascade

State the principle and clinical significance of the:

Prothrombin Time

• Principle: This test evaluates the extrinsic and common pathways of the coagulation cascade. It is performed by adding tissue thromboplastin and calcium (CaCl2​) to the patient's plasma. The normal reference range is typically 10–13 seconds.

• Clinical Significance: The PT is primarily used to monitor warfarin (Coumadin) therapy. Because the efficacy of tissue thromboplastin reagents can vary, the International Normalized Ratio (INR) was developed to provide a standardized result for these patients

Activate Partial Thromboplastin Time

• Principle: This test evaluates the intrinsic and common pathways. To mimic the contact phase in vitro, the patient's citrated plasma is incubated with kaolin (a negative surface) and phospholipids; calcium (Ca++) is then added after the incubation period to trigger the clot. The standard reference range is 28.0–35.0 seconds.

• Clinical Significance: It serves as a broad screening tool to evaluate coagulation factors and detect any inhibition of the cascade within the intrinsic system

Fibrinogen

• Principle: The patient's plasma is diluted 1:10 in buffer, and a thrombin reagent is added. The resulting clotting time is then compared against a calibration curve to deduce the exact fibrinogen concentration in mg/dL.

• Clinical Significance: This assay specifically measures the concentration of Factor I (Fibrinogen) available in the plasma to be converted into a fibrin clot

Thrombin Time

• Principle: Thrombin is added directly to the plasma to measure the specific time required for the conversion of fibrinogen to fibrin. The normal range is 10–16 seconds.

• Clinical Significance: While it measures the final step of the common pathway, it is most clinically "useful for detecting heparin contamination" in a sample

Factor Assays

• Principle: These assays are based on the ability of the patient’s plasma to correct a prolonged PT or aPTT of a known factor-deficient plasma. The test uses a linear calibration curve to determine the percentage of activity.

• Clinical Significance: These are used to determine the specific type of factor deficiency and the level of its activity. A normal activity range is generally considered to be 50–150%

Associate the coagulation factor with the screening test that is most sensitive to

Prothrombin Time (PT)

The PT is most sensitive to the extrinsic pathway and also evaluates the common pathway.

• Extrinsic Factor: Factor VII.

• Common Factors: Factors X, V, II (Prothrombin), and I (Fibrinogen).

Activated Partial Thromboplastin Time (aPTT)

The aPTT is designed to measure the intrinsic (contact) pathway and the common pathway.

• Intrinsic Factors: Factors XII, XI, IX, VIII, as well as the contact factors Prekallikrein (PK) and High-molecular-weight kininogen (HK).

• Common Factors: Factors X, V, II (Prothrombin), and I (Fibrinogen).

Thrombin Time and Fibrinogen Assay

These tests specifically target the final steps of the common pathway involving Factor I.

• Factor I (Fibrinogen): The Thrombin Time measures the speed of its conversion to fibrin, while the Fibrinogen Assay determines its actual concentration in the plasma.

Factor Assays

When a screening test (PT or aPTT) is prolonged, Factor Assays are used to identify the specific factor deficiency.

• Sensitivity: These assays are sensitive to individual factors (such as Factor VIII) by measuring the ability of a patient's plasma to "correct" the clotting time of plasma known to be deficient in that specific factor

Determine the impact pre-analytical or analytical errors may have on coagulation testing

Analytical and Reagent-Related Errors

• Reagent Variability: Historically, the efficacy of tissue thromboplastin (the reagent used for Prothrombin Time) varied widely between manufacturers. This made it difficult to accurately monitor patients on warfarin (Coumadin), as results were not standardized. To mitigate this analytical challenge, the International Normalized Ratio (INR) was developed to provide consistent results regardless of the reagent's sensitivity.

• Sensitivity Limits: The sources note a specific analytical limitation of the INR system: there is a loss of sensitivity once an INR value exceeds 4.0.

• Procedural Errors: For the aPTT test, the source emphasizes a strict sequence: the calcium (Ca++) must be added only after a specific incubation period with kaolin and phospholipids. Deviating from this procedure would likely result in an invalid or inaccurate test, as the incubation is necessary to initiate the contact phase in vitro.

Interferences and Pre-analytical Factors

• Heparin Contamination: This is a significant pre-analytical or analytical issue where heparin in the sample interferes with the results. The sources highlight that the Thrombin Time test is "really useful" for detecting this specific contamination, which would otherwise erroneously prolong clotting times.

• Inflammatory States (Biological Interference): During inflammatory events, the body produces C4b (an acute phase reactant). This protein binds to Protein S, making it non-functional. While not a laboratory "error" in the traditional sense, this biological state can lead to a measured decrease in functional Protein S, which must be accounted for during clinical interpretation